<DOC>
	<DOCNO>NCT01149655</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study consist screen period , conversion phase ( Phase 1 ) , stabilization phase ( Phase 2 ) , double-blind maintenance treatment phase ( Phase 3 ) , follow period . Subjects may either outpatient inpatient screen time reach stabilization end Phase 2 ; hospitalization study requirement . However , eligible subject must outpatients begin Phase 3 . Subjects assess weekly Phase 1 , weekly first 4 week Phase 2 3 , biweekly remain week Phases 2 3 . Subjects encourage call investigator exacerbation psychotic symptom and/or tolerability issue . The investigator also option phone subject guardian ( ) time ensure clinical stability . A data monitoring committee ( DMC ) provide oversight safety monitor review interim analysis . One interim analysis plan 75 % total expected number impend relapse event ( 28 event ) achieve conducted independent data analysis center . The DMC make recommendation stop continue study base safety efficacy review . The result interim analysis individual subject data remain blinded sponsor course study DMC determines study conclude base result interim analysis , study complete 37 endpoint event .</brief_summary>
	<brief_title>Efficacy &amp; Safety Study Oral Aripiprazole Adolescents With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Subjects current DSMIVTR diagnosis schizophrenia , history illness ( diagnosis symptom ) least 6 month prior screen . Subjects show previous response antipsychotic treatment ( clozapine ) resistant treatment antipsychotic . Subjects currently treat oral depot antipsychotic clozapine . Subjects history relapse and/or exacerbation symptom receive antipsychotic treatment . Subjects current DSMIVTR diagnosis schizophrenia . Subjects delirium , dementia , amnesia cognitive disorder ; subject psychotic symptom well account another general medical condition ( ) direct effect substance ( i.e. , medication , illicit drug use , etc. ) . Subjects attention deficit disorder attention deficit hyperactivity disorder and/or subject stimulant treatment period time last one year prior screen . Subjects neurodevelopmental disorder , except Tourette 's syndrome . Subjects experience acute depressive symptom within past 30 day prior screen . Subjects meet DSMIVTR criterion substance dependence ( include alcohol benzodiazepine , exclude caffeine nicotine ) within past 180 day prior screen . Subjects epilepsy , history seizure ( except single childhood febrile seizure posttraumatic seizure ) , history severe head trauma stroke , history current evidence unstable medical condition . Subjects history subclinical hypothyroidism ( TSH â‰¥ 4.0 mIU/L ) , know hypothyroidism hyperthyroidism ( unless condition stabilize medication least 90 day prior entry Phase 1 Phase 2 ) . Subjects medical history uncontrolled diabetes , labile unstable diabetes ( brittle diabetes ) , newly diagnose diabetes , clinically significant abnormal blood glucose level .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Adolescent</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>